Abstract：【Objective】To explore the application of bilevel positive airway pressure(BiPAP) non-invasive ventilator in patients with chronic obstructive pulmonary disease (COPD) experiencing acute exacerbation and type Ⅱ respiratory failure. 【Methods】From January 2022 to June 2023, 84 patients with COPD experiencing acute exacerbation and type Ⅱ respiratory failure were selected and randomly divided into the control group (receiving conventional nasal cannula oxygen therapy) and the observation group (receiving BiPAP non-invasive ventilator treatment), with 42 patients in each group. The levels of pulmonary function indicators [first-second forced expiratory volume (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR)], blood gas analysis indicators [arterial blood carbon dioxide partial pressure (PaCO2), arterial blood oxygen partial pressure (PaO2), arterial blood oxygen saturation (SaO2)], and serum inflammatory factors [interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP)] before and after treatment, as well as the occurrence of adverse reactions, were compared between the two groups. 【Results】After treatment, the FEV1, FVC, PEFR, PaO2, and SaO2 levels in the observation group were higher than those in the control group, while the PaCO2 and IL-6, hs-CRP levels were lower than those in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 9.52%, significantly lower than 26.19% in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】Compared with conventional nasal cannula oxygen therapy, BiPAP non-invasive ventilator applied in patients with COPD experiencing acute exacerbation and type Ⅱ respiratory failure can more effectively improve the pulmonary function and blood gas indicators, reduce the levels of serum inflammatory factors, and the total incidence of adverse reactions, and has higher safety.
2025, Vol. 42 
